Medical Disorders
Resources
Basic InformationLookupsLatest News
FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12AHA News: Half of U.S. Adults Should Monitor Blood Pressure at Home, Study SaysWidely Prescribed Class of Meds Might Raise Dementia Risk9/11 Dust Linked to Prostate Cancer in First RespondersOcean Swimming Causes Skin Changes: StudyNew Drug Combats Leading Cause of DwarfismAHA News: What Migraine Sufferers Need to Know About Stroke RiskNorovirus Fears Stir Recall of Frozen BlackberriesFlying Insects in Hospitals Carry 'Superbug' GermsU.S. Cases of Infant Gut Illness Plummet After Vaccine IntroducedAHA News: This Faulty Gene May Help Predict Heart Muscle DiseaseCell Mapping Provides New Insights About AsthmaHealth Tip: Recognizing Balance DisordersThe Safer Way to Ease Post-Surgical PainSudden Death Can Occur Even in Well-Controlled EpilepsyStatins May Lower Risk of Stroke After Cancer RadiotherapyExperimental Drug Shows Early Promise Against Sickle Cell DiseaseVitamin D Supplements May Not Help Your HeartHow to Head Off a Pain in the NeckSprouts Supermarkets Recalls Frozen Spinach Due to Listeria FearsA-Fib Can Raise Dementia Risk, Even in Absence of StrokeAnother Climate Change Threat: More 'Flesh-Eating' Bacteria?Heading to Europe This Summer? Get Your Measles ShotAiling Heart Can Speed the Brain's Decline, Study FindsHealth Tip: Preventing GlaucomaHead Injuries Tied to Motorized Scooters Are Rising: StudyOverweight Kids Are at Risk for High Blood PressureHot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. CitiesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyHealth Tip: Early Signs of Lyme DiseaseHealth Tip: Hiccup Home Remedies
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Orders Label Warning on Alcohol Use With 'Female Viagra'

HealthDay News
by -- Robert Preidt
Updated: Apr 12th 2019

new article illustration

FRIDAY, April 12, 2019 (HealthDay News) -- A drug touted as a "female Viagra" can cause severe low blood pressure and fainting when used with alcohol, the U.S. Food and Drug Administration warns.

As a result, the agency has ordered the drug's maker Sprout Pharmaceuticals to make a safety labeling change to Addyi (flibanserin).

The boxed warning, contraindication, warnings and precautions, and adverse reactions sections of the drug's labeling will advise women to stop drinking alcohol at least two hours before taking Addyi at bedtime or to skip the Addyi dose that evening. The drug is prescribed to be taken once daily, generally at bedtime.

Women should not drink alcohol until at least the morning after a dose of Addyi, the FDA said.

The FDA approved the drug in August 2015 to treat low sexual desire in older women. The order for the labeling change followed a review of postmarketing studies of Addyi.

An FDA statement said the agency ordered the labeling change as Sprout continued to push for removing the boxed warning and contraindication about alcohol. "Based on a careful review of available data … removing this important safety information was not acceptable for the protection of public health," the FDA statement said.

Sprout conducted one of the postmarketing studies as a condition of Addyi's FDA approval. Though there were no reports of severe low blood pressure or fainting requiring treatment among participants, safety precautions built into the study did not allow adequate assessment of this risk, according to the FDA.

During the study, women who had low blood pressure while lying down or related symptoms such as dizziness weren't allowed to stand up for blood pressure readings. Or, they were required to have repeated readings while lying down until their results were high enough so they could safely stand.

As a result, study data had missing or delayed measurements from these women, FDA said.

There were many more missing or delayed blood pressure readings when women took Addyi and alcohol together than when they took either alone. The greatest number of missing readings occurred near the time when the drug's blood levels were highest in women taking Addyi with alcohol, according to the FDA.

This pattern of missing or delayed blood pressure readings "provides further evidence of an interaction between Addyi and alcohol that can increase the risk of" low blood pressure and fainting, the FDA said.

Other postmarketing studies found that the risk of severe low blood pressure and fainting was lower when women who had at least two alcoholic drinks waited at least two hours before taking Addyi.

Sprout has until April 16 to appeal the order.

More information

The Mayo Clinic has more on low sex drive in women.




Facebook

Amazon Smile

To quit smoking, call Connecticut QuitLine at 1-800-QUIT-NOW.

Children and Adult services are available now with no wait time.  Please contact HBH Intake Department at 860-548-0101, option 2.

 


powered by centersite dot net